Handelsbanken Fonder
TXMD icon

Handelsbanken Fonder’s TherapeuticsMD TXMD Stock Holding History

Handelsbanken Fonder’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-65,000
Closed -$3.92M – 1590
2020
Q4 		$3.92M Buy
65,000
+15,000
+30% +$1.02M 0.02% 460
2020
Q3 		$3.92M Buy
+50,000
New +$3.99M 0.03% 406

Other funds holding TXMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Handelsbanken Fonder's TXMD Position: Q1 2021 in Review

Handelsbanken Fonder sold out of TherapeuticsMD (TXMD) in Q1 2021, closing a stake of 65,000 shares — an estimated $3.92M sold.

Handelsbanken Fonder first reported a position in TXMD in Q3 2020 and held it in 2 quarters. The position peaked at $3.92M in Q3 2020. 160 funds tracked by Wall St. Rank hold TXMD as of Q1 2021.

  • Handelsbanken Fonder reported no remaining TherapeuticsMD position as of Q1 2021 after selling out during the quarter.
  • Handelsbanken Fonder sold 65,000 TherapeuticsMD shares in Q1 2021, an estimated $3.92M.
  • Handelsbanken Fonder first reported a position in TherapeuticsMD in Q3 2020 and held it in 2 quarters.
  • Handelsbanken Fonder's TherapeuticsMD position peaked at $3.92M in Q3 2020.
  • 160 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2021.

Based on Handelsbanken Fonder's 13F filing for Q1 2021, filed 29 Apr 2021.